Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Accured Expenses: 2017-2023

Historic Change in Accured Expenses for Dianthus Therapeutics (DNTH) over the last 3 years, with Jun 2023 value amounting to -$1.7 million.

  • Dianthus Therapeutics' Change in Accured Expenses fell 169.82% to -$1.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$2.6 million, marking a year-over-year decrease of 709.15%. This contributed to the annual value of $973,000 for FY2022, which is 535.95% up from last year.
  • As of Q2 2023, Dianthus Therapeutics' Change in Accured Expenses stood at -$1.7 million, which was up 49.66% from -$3.3 million recorded in Q1 2023.
  • Dianthus Therapeutics' 5-year Change in Accured Expenses high stood at $3.7 million for Q4 2019, and its period low was -$3.3 million during Q1 2023.
  • Moreover, its 2-year median value for Change in Accured Expenses was -$741,000 (2022), whereas its average is -$674,500.
  • Per our database at Business Quant, Dianthus Therapeutics' Change in Accured Expenses soared by 643.89% in 2019 and then plummeted by 288.71% in 2023.
  • Over the past 4 years, Dianthus Therapeutics' Change in Accured Expenses (Quarterly) stood at $3.7 million in 2019, then crashed by 55.68% to -$2.5 million in 2020, then reached $1.5 million in 2022, then tumbled by 169.82% to -$1.7 million in 2023.
  • Its Change in Accured Expenses was -$1.7 million in Q2 2023, compared to -$3.3 million in Q1 2023 and $1.5 million in Q4 2022.